Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 12/11/2024
• Auteurs : P. AdrichP. BlumerG. CaratschM. ChungPierre CladéP. CominiP. CrivelliO. DalkarovP. DebuA. DouilletD. DrapierP. FroelichNabil GarroumSaïda Guellati-KhélifaJ. GuyomardPaul-Antoine HervieuxLaurent HilicoPaul IndelicatoS. JonsellJean-Philippe KarrB. KimS. KimE.-S. KimY. KoT. KosinskiN. KurodaB.M. LataczB. LeeH. LeeJ. LeeE. LimL. LiszkayD. LunneyGiovanni ManfrediB. MansouliéM. MatusiakV. NesvizhevskyF. NezS. NiangBen OhayonK. ParkNancy PaulP. PérezC. RegenfusSerge ReynaudCorentin RoumegouJ.-Y. RousséY. SacquinG. SadowskiJ. SarkisyanM. SatoF. Schmidt-KalerM. StaszczakK. SzymczykT. TanakaB. TuchmingB. VallageAnatoli VoroninD.P. van der WerfA. WelkerD. WongS. WronkaY. YamazakiK.-H. YooPauline Yzombard
• Organismes : National Center for Nuclear Research Institute for Particle Physics and Astrophysics [ETH Zürich] Institute for Particle Physics and Astrophysics [ETH Zürich] Ulsan National Institute of Science and Technology Laboratoire Kastler Brossel Institut de Recherches sur les lois Fondamentales de l'Univers Institute for Particle Physics and Astrophysics [ETH Zürich] CERN [Genève] Institut de Recherches sur les lois Fondamentales de l'Univers Université d'Évry-Val-d'Essonne Laboratoire Kastler Brossel Laboratoire Kastler Brossel Stockholm University Department of Physics [Stockholm] Angström Laboratory Laboratoire de Physique Nucléaire et de Hautes Énergies Laboratoire Kastler Brossel Laboratoire Kastler Brossel Laboratoire commun de métrologie LNE-CNAM Laboratoire Kastler Brossel Institut de Physique et Chimie des Matériaux de Strasbourg Université d'Évry-Val-d'Essonne Laboratoire Kastler Brossel Laboratoire Kastler Brossel Department of Physics [Stockholm] Laboratoire Kastler Brossel Université d'Évry-Val-d'Essonne Korea Basic Science Institute Department of Physics and Astronomy [Seoul] Korea University [Seoul] Institute for Basic Science [Daejeon] National Centre for Nuclear Research [Otwock] The University of Tokyo Institut de Recherches sur les lois Fondamentales de l'Univers Seoul National University [Seoul] Department of Physics and Astronomy [Seoul] Institute for Basic Science [Daejeon] Korea University [Seoul] Institut de Recherches sur les lois Fondamentales de l'Univers Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Institut de Physique et Chimie des Matériaux de Strasbourg Institut de Recherches sur les lois Fondamentales de l'Univers National Centre for Nuclear Research [Otwock] Institut Laue-Langevin Laboratoire Kastler Brossel Laboratoire de Physique des 2 Infinis Irène Joliot-Curie CERN [Genève] Institute for Particle Physics and Astrophysics [ETH Zürich] Institute for Basic Science [Daejeon] Department of Physics and Astronomy [Seoul] Laboratoire Kastler Brossel Institut de Recherches sur les lois Fondamentales de l'Univers Institute for Particle Physics and Astrophysics [ETH Zürich] Laboratoire Kastler Brossel Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Institut de Recherches sur les lois Fondamentales de l'Univers Institut de Recherches sur les lois Fondamentales de l'Univers Institut de Recherches sur les lois Fondamentales de l'Univers Institute for Particle Physics and Astrophysics [ETH Zürich] The University of Tokyo Institut für Physik [Mainz] National Centre for Nuclear Research [Otwock] National Centre for Nuclear Research [Otwock] The University of Tokyo Institut de Recherches sur les lois Fondamentales de l'Univers Institut de Recherches sur les lois Fondamentales de l'Univers CERN [Genève] Department of Physics [Swansea] CERN [Genève] Department of Physics and Astronomy [Seoul] National Centre for Nuclear Research [Otwock] Saitama University Ulsan National Institute of Science and Technology Laboratoire Kastler Brossel
• Publié dans European Physical Journal C: Particles and Fields le 23/10/2020

---

Résumé : We report on the first production of an antihydrogen beam by charge exchange of 6.1 keV antiprotons with a cloud of positronium in the GBAR experiment at CERN. The 100 keV antiproton beam delivered by the AD/ELENA facility was further decelerated with a pulsed drift tube. A 9 MeV electron beam from a linear accelerator produced a low energy positron beam. The positrons were accumulated in a set of two Penning–Malmberg traps. The positronium target cloud resulted from the conversion of the positrons extracted from the traps. The antiproton beam was steered onto this positronium cloud to produce the antiatoms. We observe an excess over background indicating antihydrogen production with a significance of 3–4 standard deviations.

---

Fichiers liés : s10052-024-13515-w.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 11/11/2024
• Auteurs : Bastien LaperrousazBenoît LevastMathieu FontaineStéphane NanceyPierre DechelotteJoel DorePhilippe Lehert
• Organismes : MaaT Pharma [Lyon] MaaT Pharma [Lyon] MaaT Pharma [Lyon] Service d'Hépatologie et de Gastroentérologie [Lyon] Hospices Civils de Lyon Autophagie infection et immunité - Autophagy Infection Immunity [CIRI] Centre International de Recherche en Infectiologie Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau Institute for Research and Innovation in Biomedicine Université de Rouen Normandie Service de Nutrition [CHU Rouen] MetaGenoPolis MICrobiologie de l'ALImentation au Service de la Santé UCL Crypto Group University of Melbourne
• Publié dans BMC Gastroenterology le 01/11/2020

---

Résumé : BackgroundMultiple studies have evaluated fecal microbiota transfer (FMT) in patients with ulcerative colitis (UC) using single-donor (SDN) and multidonor (MDN) products. Systematic review and meta-analysis were performed to compare the safety of SDN and MDN products.MethodsSystematic searches were performed in Web of Science, Scopus, PubMed, and Orbit Intelligence to identify studies that compared FMT products manufactured using SDN or MDN strategies against control treatment in patients with UC. Fifteen controlled studies were selected for meta-analysis (11 randomized controlled trials and 4 controlled cohort trials). Safety of each treatment type was assessed using the counts of adverse events and serious adverse events using fixed- and random-effects models. Significance of the indirect difference between FMT preparations was assessed using a network approach. Benefit-risk ratios were calculated by multiplicative utility model, incorporating geometric mean of risk ratios (RRs) of efficacy and safety.ResultsSafety data was collected for a total of 587 patients (193 exposed to SDN products, 114 exposed to MDN products and 280 exposed to control treatment). The 12 studies showed similar overall safety event counts for MDN and SDN versus placebo (RRs: 0.90 and 1.09, respectively [P = 0.206 and P = 0.420, respectively]). Results indicated similar risk of safety events for MDN compared to SDN (RR: 0.83, P = 0.159). Positive benefit-risk ratios were demonstrated for MDN and SDN versus placebo (RRs: 1.70 and 1.16, respectively [P = 0.003 and P = 0.173, respectively]). MDN had a greater benefit-risk ratio compared to SDN (RR: 1.46, P = 0.072).ConclusionSimilar safety profiles were observed for MDN and SDN strategies. Alongside previously described superior efficacy, treatment with MDN has greater benefit-risk ratio than SDN in patients with UC. Further development of MDN FMT treatment for UC should be considered.

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 10/11/2024
• Auteurs : Raghiatou BaldéLambert AssoumouChristine KatlamaBaptiste AbbarPierre DelobelThierry AllegreArmelle LavoleAlain MakinsonOlivia Zaegel-FaucherLaurent GreillierCathia SouliéMarianne VeyriMathilde BertheauMichèle Algarte GeninSéverine GibowskiAnne-Geneviève MarcelinKevin BihanMarine BaronDominique CostagliolaOlivier LambotteJean-Philippe Spano
• Organismes : Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Centre d'Immunologie et des Maladies Infectieuses Service Maladies infectieuses et tropicales [CHU Toulouse] Centre Hospitalier d'Aix en Provence [Aix-en-Provence] CHU Tenon [AP-HP] Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes Département Maladies Infectieuses et Tropicales [CHRU Montpellier] Aix Marseille Université Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM] Multidisciplinary Oncology and Therapeutic Innovations Unit / Service d’Oncologie Multidisciplinaire et d’Innovations Thérapeutiques Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique ANRS - Maladies infectieuses émergentes Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] ANRS - Maladies infectieuses émergentes CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière] CHU Pitié-Salpêtrière [AP-HP] Centre d'Immunologie et des Maladies Infectieuses Institut Pierre Louis d'Epidémiologie et de Santé Publique Service de Médecine interne - Immunologie clinique [Kremlin-Bicêtre] Université Paris-Saclay CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique

---

Résumé : Background: immune checkpoint inhibitors (ICIs) have been a major advance in cancer management. However, we still lack prospective real-world data regarding their usage in people with HIV infection (PWH). Materials and methods: the ANRS-CO24-OncoVIHAC study (NCT03354936) is an ongoing prospective observational cohort study in France of PWH with cancer treated with ICI. We assessed the incidence of grade ≥3 immune-related adverse events (irAEs). All grade ≥3 irAEs were reviewed by an Event Review. Results: between 17 January 2018 and 5 December 2023, 150 participants were recruited from 33 sites and 140 were included in this analysis. At the data cut-off date of 5 December 2023, median follow-up was 9.2 months (IQR 3.9–18.3), with a total of 126.2 person-years. Median age was 59 years (IQR 54–64) and 111 (79.3%) were men. Median time since HIV diagnosis was 25 years (12–31), median duration on ARV was 19.5 years (7.7–25.4) and the CD4 nadir was 117/µl (51–240). ICI regimens comprised anti-programmed cell death protein 1 (PD1) for 111 (79.3%) participants, anti-programmed death-ligand 1 (PDL1) for 25 (17.9%), a combination of anti-PD1 and anti-human cytotoxic T-lymphocyte-associated protein 4 (CTLA4) for three (2.1%), and anti-PD1 along with anti-vascular endothelial growth factor (VEGFR) for one (0.7%). The most frequent cancers were lung (n = 65), head/neck (n = 15), melanoma (n = 12), liver (n = 11) and Hodgkin lymphoma (n = 9). During follow-up, a total of 34 grade ≥3 irAEs occurred in 20 participants, leading to an incidence rate of 26.9 per 100 person-years. The Kaplan-Meier estimates of the proportion of participants with at least one episode of grade ≥3 irAEs were 13.8% at 6 months, 15.0% at 12 months and 18.7% at 18 months. One treatment-related death due to myocarditis was reported (0.7%). Multivariable analysis of cumulative incidence showed that participants with time since HIV diagnosis >17 years (incidence rate ratio [IRR] 4.66, p = 0.002), with CD4 <200 cells/µl (IRR 4.39, p < 0.0001), with positive cytomegalovirus (CMV) serology (IRR 2.76, p = 0.034), with history of cancer surgery (IRR 3.44, p = 0.001) had a higher risk of incidence of grade ≥3 irAEs. Conclusions: this study showed that the incidence of a first episode of grade ≥3 irAE was 15.0% (95% CI 9.6–22.9) at 1 year and the cumulative incidence of all severe irAE episodes was 26.9 per 100 person-years. Low CD4 count, positive CMV serology, history of cancer surgery and a longer time since HIV diagnosis were associated with the occurrence of severe irAEs.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/11/2024
• Auteurs : Cassandra NormandinFrédéric FrappartLuc BourrelFabien BlarelSylvain BiancamariaJean-Pierre WigneronLéonie GalenonEmilie BernardLudovic CoulonBertrand LubacVincent MarieuVincent VantrepotteBinh Pham-DucHuy Toan DoCatherine PrigentFilipe AiresDai YamazakiPhilippe Ciais
• Organismes : Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère Géosciences Environnement Toulouse Laboratoire d'études en Géophysique et océanographie spatiales Laboratoire d'études en Géophysique et océanographie spatiales Interactions Sol Plante Atmosphère Laboratoire d'études en Géophysique et océanographie spatiales Laboratoire d'études en Géophysique et océanographie spatiales Laboratoire d'études en Géophysique et océanographie spatiales Environnements et Paléoenvironnements OCéaniques Environnements et Paléoenvironnements OCéaniques Laboratoire d’Océanologie et de Géosciences (LOG) - UMR 8187 Vietnam Academy of Science and Technology [Hanoi] Laboratoire d'Etude du Rayonnement et de la Matière en Astrophysique et Atmosphères = Laboratory for Studies of Radiation and Matter in Astrophysics and Atmospheres Laboratoire d'Etude du Rayonnement et de la Matière en Astrophysique et Atmosphères = Laboratory for Studies of Radiation and Matter in Astrophysics and Atmospheres University of Tokyo [Kashiwa Campus] Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette]
• Publié dans Science of the Total Environment le 29/10/2020

---

Résumé :

---

Fichiers liés : 1-s2.0-S0048969724054093-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/11/2024
• Auteurs : Annicet-Clotaire DikoumbaPierre Philippe Mbehang NguemaLeresche Even Doneilly Oyaba YindaRoméo Wenceslas LendambaJean Constan Obague MbeangGuy Roger Ndong AtomeZinga-Koumba Christophe RolandSylvain GodreuilRichard Onanga
• Organismes : Centre Interdisciplinaire de Recherches Médicales de Franceville Institut de Recherche en Ecologie Tropicale Centre Interdisciplinaire de Recherches Médicales de Franceville Centre de Recherches Médicales de Lambaréné Institut de Recherche en Ecologie Tropicale Departement de Chimie Institut de Recherche en Ecologie Tropicale Département de Bactériologie-Virologie [CHRU Montpellier] Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle Centre Interdisciplinaire de Recherches Médicales de Franceville
• Publié dans Antibiotics le 24/10/2020

---

Résumé : Background: In Gabon, studies on the characterization of extended-spectrum beta-lactamase-producing Escherichia coli in young children with diarrhoea are almost nonexistent. The objective was to evaluate the prevalence of antibiotic resistance to extended-spectrum beta-lactamase-producing Escherichia coli in children at public hospitals in Franceville, Gabon. Methods: Seventy diarrhoea faecal samples were collected from children aged 0–5 years. The culture and isolation of colonies were carried out on MacConkey agar. The colonies were identified using VITEK 2. The determination of the extended-spectrum beta-lactamase’s profiles was accomplished using the double disk method. The identification of phylogroups and pathotypes was performed by PCR. Identification of the ESBL genes was performed by sequencing. Results: A total of 26 strains of Escherichia coli (33.0%) were identified from 78 bacterial isolates. Twenty (77.0%) Escherichia coli strains carried extended-spectrum beta-lactamases blaCTX-M-15 and 5.0% carried blaSHV-12 subtypes. Phylogroup D (62.0%) was predominant, followed by B1 (12.0%), B2 (8.0%) and E (4.0%). The bacterial pathogens causing diarrhoea were enterohemorrhagic E. coli (12.0%), typical enteropathogenic Escherichia coli (8.0%), atypical enteropathogenic Escherichia coli (4.0%), Enteroaggregative Escherichia coli (4.0%) and enteroinvasive E. coli (4.0%). Conclusions: This study showed a high prevalence of extended-spectrum beta-lactamase, Escherichia coli of phylogroup D and pathotype enterohemorrhagic Escherichia coli in children under 5 years old in public hospitals in Franceville, most probably due to the misuse or inappropriate consumption of beta-lactams.

---

Fichiers liés : antibiotics-13-01059.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/11/2024
• Auteurs : Antoine JouvenelAdrien TassouMaxime ThouayeJérôme RuelMyriam AntriJean-Philippe LeyrisAurore GiraudinSylvie MalliéChamroeum SarLucie DiouloufetCorinne SonrierFrançois DaubeufJuliette BertinStacy AlvesStéphanie VentéoNelly FrossardPatrick CarrollIlana MechalyDidier RognanPierre SokoloffRadhouane DallelPatrick DelmasJean ValmierCyril Rivat
• Organismes : Institut des Neurosciences de Montpellier Institut des Neurosciences de Montpellier Institut des Neurosciences de Montpellier Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research Neuro-Dol Neuro-Dol Institut des Neurosciences de Montpellier Institut des Neurosciences de Montpellier Institut des Neurosciences de Montpellier Institut des Neurosciences de Montpellier Laboratoire d'Innovation Thérapeutique Institut des Neurosciences de Montpellier Institut des Neurosciences de Montpellier Institut des Neurosciences de Montpellier Laboratoire d'Innovation Thérapeutique Institut des Neurosciences de Montpellier Institut des Neurosciences de Montpellier Laboratoire d'Innovation Thérapeutique Neuro-Dol Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research Institut des Neurosciences de Montpellier Institut des Neurosciences de Montpellier
• Publié dans Nature Communications le 23/10/2020

---

Résumé : Navigating the duality of opioids' potent analgesia and side effects, including tolerance and hyperalgesia, is a significant challenge in chronic pain management, often prompting hazardous dose escalation to maintain analgesic effects. The peripheral mu-opioid receptor (MOR) is known to mediate these contradictory effects. Here, we show that the fms-like tyrosine kinase receptor 3 (FLT3) in peripheral somatosensory neurons drives morphine tolerance and hyperalgesia in a male rodent model. We found that chronic morphine treatment increases FLT3 and MOR co-expression, and that inhibiting FLT3 represses MOR-induced hyperactivation of the cyclic adenosine monophosphate (cAMP) signaling pathway, mitigating maladaptive excitatory processes engaged after chronic morphine treatment. Furthermore, in postsurgical or inflammatory models of chronic pain, co-administering morphine with a FLT3specific inhibitor not only prevents or suppresses tolerance and hyperalgesia but also potentiates the analgesic efficacy of morphine, without aggravating other morphine-induced adverse effects. Our findings suggest that pairing morphine with FLT3 inhibitors could become a promising avenue for chronic pain management to safely harness the power of opioids, without the risk of dose escalation. By enhancing morphine analgesic potency through FLT3 inhibition, this approach could minimize opioid dosage, thereby curtailing the risk of addiction and other opioid-related side effects.

---

Fichiers liés : s41467-024-54054-y.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/11/2024
• Auteurs : Julie MésinèleManon RuffinLoïc GuillotPierre-Yves BoëlleHarriet CorvolMichel AbellyNathalie AllouBaptiste ArnouatCarole Bailly PicciniChantal BelleguicKatia BessaciTiphaine BihoueeYves BillonFrançois BremontJacques BrouardStéphanie BuiPierre-Régis BurgelBoubou CamaraKarine CampbellRaphael ChironEmmanuelle Coirier-DuetHarriet CorvolLaure CossonMarie-Laure DalphinIsabelle Danner-BoucherValérie DavidÉric DeneuvillePhilippe DomblidesStéphane DominiqueJean-Christophe DubusNadine DufeuIsabelle DurieuSandra DuryRalph EpaudAnnlyse FantonMichael FayonPierre FoucaudMichèle GerardinJean-Louis GiniesDominique GrenetMarie-Christine HeraudVéronique HoudouinDominique HubertFrédéric HuetRomain KesslerAlice LadauradeJeannes LanguepinMuriel LauransPascal Le RouxOlivier Le RouzicSylvie LeroyCathie LlerenaJulie MaceyJulie MankikianChristophe MarguetLaurent MelyMarie MittaineAnne MunckMarlène Murris-EspinNadia NathanRaphaëlle Nove-JosserandCaroline PerissonIsabelle PinSophie RamelCinthia RamesGilles RaultPhilippe ReixNatacha RemusMartine Reynaud-GaubertBénédicte Richaud-ThiriezManuëla Scalbert-DujardinIsabelle Sermet-GaudelusNathalie StremlerVéronique StorniAurélie TatopoulosGuillaume ThouveninFrançoise TroussierPhilippe VigneronLaurence WeissNathalie Wizla
• Organismes : Centre de Recherche Saint-Antoine CHU Trousseau [APHP] Sorbonne Université
• Publié dans Scientific Reports le 26/10/2020

---

Source

---

• Type de publi. :
• Date de publi. : 06/11/2024
• Auteurs : Junteng WuAngelica BiancoAgnès BorbonLaurent DeguillaumeEvelyn FreneyPierre AmatoJean-Luc BarayAurélie ColombMarie MonierClémence RoseEtienne BrugereLaëtitia BouvierRégis DupuyPatrick FrévilleJean-Marc PichonMickael RibeiroPhilippe CacaultAntoine CanziLéa DupontFrederic MathonatPauline NibertFrederic PeyrinRyan Puyd'HommeYi Wu
• Organismes : Laboratoire de Météorologie Physique Laboratoire de Météorologie Physique Laboratoire de Météorologie Physique Laboratoire de Météorologie Physique Observatoire de Physique du Globe de Clermont-Ferrand Laboratoire de Météorologie Physique Institut de Chimie de Clermont-Ferrand Laboratoire de Météorologie Physique Observatoire de Physique du Globe de Clermont-Ferrand Laboratoire de Météorologie Physique Laboratoire de Météorologie Physique Laboratoire de Météorologie Physique Laboratoire de Météorologie Physique Observatoire de Physique du Globe de Clermont-Ferrand Laboratoire de Météorologie Physique Observatoire de Physique du Globe de Clermont-Ferrand Observatoire de Physique du Globe de Clermont-Ferrand Laboratoire de Météorologie Physique Observatoire de Physique du Globe de Clermont-Ferrand Laboratoire de Météorologie Physique Laboratoire de Météorologie Physique Institut de Chimie de Clermont-Ferrand Laboratoire de Météorologie Physique Observatoire de Physique du Globe de Clermont-Ferrand Laboratoire de Météorologie Physique Laboratoire de Météorologie Physique Institut de Chimie de Clermont-Ferrand

---

Résumé : The composition of atmospheric organic matter is extremely complex and influenced by emissions, which can be natural (such as plant emissions) or anthropogenic (linked to human activity), but also by atmospheric transformations. Organic compounds react with the main atmospheric oxidants (ozone, hydroxyl radicals and nitrate) and undergo chemical aging in this environment in different forms: in gas, condensed on particles or even dissolved in cloud droplets. The equilibrium of organic matter is managed mainly by its physicochemical properties (i.e., volatility, polarity) and environmental conditions. The atmosphere also shelters the atmospheric microbiota (a diversity of microorganisms such as bacteria, yeasts or even molds), which degrades organic matter for their metabolism and produces new compounds. These biological processes in the atmosphere potentially rise to organic transformations that are still unknown. To characterize the composition and reactivity of atmospheric organic matters in these three phases, a measurement campaign RACLET (Reactive gases, Aerosols and CLouds: Exploring organic matter Transformations) was organized by LaMP (Laboratoire de Météorologie Physique) and OPGC (Observatoire de la Physique du Globe de Clermont Ferrand) in April 2024 at the Puy de Dôme atmospheric observatory[1]. In addition to the on-going routine measurements at the observatory, the collaboration of several national and international laboratories, made it possible to deploy a wide range of state-of-the-art instruments to complete the measurement of chemical composition and meteorological conditions. These instruments included; two proton transfer mass spectrometers (PTR-Q-MS and PTR-Tof-MS), a CHemical Analysis of aeRosol ON-line module (CHARON), an Aerosol Composition and Speciation Monitor (ACSM), a fog monitor (DMT), a snow particle counter (ST Niigata), a direct optical measurement of bioaerosols (WIBS), TEM collector, a recent in-situ aerosol instrument (SMPS), and two Formaldehyde instruments (Aerolaser and PICARRO). Lidar measurements and multi-frequency radar measurements were performed at Cézeaux and Opme to characterize the vertical and horizontal extensions of the clouds sampled at puy de Dôme and of the dust event. The dynamical context was also characterized by retro trajectory calculations throughout the entire period duration of the campaign with CAT - ECMWF ERA5.

---

Fichiers liés : 8th sino french workshop Bordeaux RACLET poster.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 05/11/2024
• Auteurs : Jill CorreJérôme LambertArthur BobinSalomon ManierAurore PerrotLionel KarlinMurielle RousselNoemie BigotOmar BenbrahimOlivier Thierry AllangbaPhilippe ReyVeronique DorvauxMarguerite VignonVirginie RolandReda GaridiJean-Noel BastieMarie-Lorraine ChrétienSophie GodetLydia MontesBrieuc CherelThomas ChalopinBorhane SlamaKamel LaribiClaire DingremontChristophe RoulValentine RichezClara MarietteSophie RigaudeauClaire CalmettesMamoun DibMourad TiabLaure VincentJacques DelaunayJean-Pierre MarolleauPascal GodmerLaurent FrenzelRonan Le CallochEmilie ChalayerHélène GardeneyMargaret MacroBruno RoyerOlivier DecauxBertrand ArnulfKarim Belhadj MerzougCyrille TouzeauMohamad MohtyAurelie GontierAmine KasmiPhilippe MoreauThierry FaconHerve Avet LoiseauCyrille HulinXavier Leleu
• Organismes : Institut Universitaire du Cancer de Toulouse - Oncopole Hopital Saint-Louis [AP-HP] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Université de Lille Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 Centre Hospitalier Régional Universitaire [CHU Lille] Service Hématologie - IUCT-Oncopole [CHU Toulouse] Immuno-Biologie des Lymphomes [CIRI] Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL] Contrôle de la Réponse Immune B et des Lymphoproliférations Service de biostatistique et information médicale de l’hôpital Saint Louis (Equipe ECSTRA) Hopital Saint-Louis [AP-HP] Centre Hospitalier Regional d'Orléans Centre Léon Bérard [Lyon] Centre hospitalier régional de Metz-Thionville Hôpital Cochin [AP-HP] Université de Mons = University of Mons Université de Versailles Saint-Quentin-en-Yvelines Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Lipides - Nutrition - Cancer [Dijon - U1231] Hôpital Robert Debré CHU Amiens-Picardie Centre hospitalier Bretagne Atlantique (Morbihan) Centre Hospitalier Henri Duffaut [Avignon] Centre Hospitalier Le Mans (CH Le Mans) CHU Amiens-Picardie HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666
• Publié dans Blood le 28/10/2020

---

Résumé : Introduction: Isa-VRd significantly increased the MRD negative rate at 10-5 (NGS) at 18 months compared to IsaRd (OR for MRD negativity 3.16, 95%CI 1.89-5.28, p<0.0001), the primary endpoint of BENEFIT study, including in high-risk (HR) NDMM TI. HR was initially defined using the IFM linear predictor (LP) cytogenetic score(HR if LP >1)according to Perrot et al in BENEFIT. The IMS has recently attempted to standardize the HR definition based on several genomic abnormalities alone [deletion 17p in more than 20% of sorted plasma cells, TP53 mutation, del(1p32)del/del] or in combination [t(4;14) or t(14;16) or t(14;20) +gain/amp 1q or del(1p32)del/wt, gain/amp 1q +del(1p32)del/wt].We planned to investigate the efficacy of Isa-VRd over IsaRd in HR NDMM TI using the novel definition. Methods: BENEFIT is a prospective, multicenter, randomized, open-label, phase 3 study done at 68 IFM study sites in France. Patients were randomized 1:1 and stratified by age, centers and high-risk MM to receive Isa-VRd or IsaRd. Isa-VRd arm received V weekly for 12 months then day 1 and 15 up to 18 months; both arms received a classical IsaRd with d permanently discontinued at 12 months. At a median follow-up of 23.5 months, a total of 270 patients were enrolled with 135 assigned to either Isa-VRd or IsaRd arms, and received at least one dose of treatment. Data are presented in ITT. IMS new HR definition was defined based on targeted next generation sequencing of sorted plasma cells. Results: HR features characterized 32 (24%) patients and 24 (18%) across Isa-VRd or IsaRd arms using the IMS HR definition. Deletion 17p 10 (7%) and 7 (5%), TP53 mutation 6 (4%) and 5 (4%), del(1p32)del/del 1 (1%) and 0, t(4;14) or t(14;16) or t(14;20) +gain/amp 1q or del(1p32)del/wt 13 (10%) and 10 (7%), gain/amp 1q +del(1p32)del/wt 6 (4%) and 5 (4%), respectively across arms. Overall, the new IMS HR definition reclassified 30 (13%) NDMM TI patients in the HR category compared to the IFM LP score. Of note, the HR patients according to the IFM LP score were all considered HR by the new IMS definition.The 18-months MRD negativity rate at 10-5 was higher for Isa-VRd in high-risk NDMM TI with the IMS HR definition, 18 (56%) and 6 (25%) across arms, [odds ratio (OR) for MRD negativity in Isa-VRD group compared to IsaRd group was 3.86 (95%CI, 1.2 to 12.3)]. Similar data were observed at 10-6 at 18 months, 16 (50%) and 6 (25%) across arms [OR 3.00 (95%CI, 0,95 to 9.52)]. Higher MRD negativity rates were also observed at 12 months at both 10-5 and 10-6 and in patients with a response ≥ CR and MRD negative status in Isa-VRd in HR NDMM TI.The 18-month MRD negativity rate at 10-5 was higher for Isa-VRd also in NON high-risk NDMM TI (IMS HR definition) [OR 3.00 (95%CI, 1.7 to 5.3)], as well as at 10-6 [OR 2.61 (95%CI, 1.3 to 5.0)] and at 12 months at both 10-5 and 10-6 thresholds and in patients with a response ≥ CR and MRD negative status. Although no statistically significant interaction was detected across HR and NON HR, the greater benefit of IsaVRD vs. IsaRd for MRD negativity was systematically higher for HR patients, regardless of the timepoints (12 months, 18 months), MRD thresholds (10-5 or 10-6) and MRD negativity definition (≥CR or not) Conclusions: The results from the BENEFIT study demonstrated meaningful benefit of the quadruplet-based Isa-VRd regimen compared to IsaRd in all NDMM TI patients. Of importance, the benefit of the Isa-VRd regimen was greater in HR compared to NON HR NDMM TI patients. This data supports Isa-VRd as a new SOC for NDMM TI aged of 65 to 79 patients over the current triplet-based SOC DRd, particularly for HR NDMM TI.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/11/2024
• Auteurs : Julian TheurietMarion MasingueAnthony BéhinAna FerreiroGuillaume BassezPauline JaubertOriana TarabayFrédéric FerAntoine PegatFrançoise BouhourJuliette SvahnPhilippe PetiotLaurentiu JomirGuy ChauplannazCatherine Cornut-ChauvincVéronique ManelEmmanuelle Salort-CampanaShahram AttarianEtienne FortanierAnnie VerschuerenLudivine KoutonJean-Philippe CamdessanchéCéline TardArmelle MagotYann PéréonJean-Baptiste NouryMarie-Christine Minot-MyhieMaud PerieFrederic TaitheYacine FarhatAnne-Laure MilletPascal CintasGuilhem SoléMarco SpinazziFlorence EsselinDimitri RenardSabrina SacconiAndra EzaruEdoardo MalfattiMartial MallaretLaurent MagyEva DiabPhilippe MerleMaud MichaudMaxime FournierAleksandra Nadaj PaklezaJean-Baptiste ChansonClaire LefeuvrePascal LaforetPascale RichardDamien SternbergRocio-Nur Villar-QuilesTanya StojkovicBruno Eymard
• Organismes : Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Physiopathologie et génétique du neurone et du muscle / Pathophysiology and Genetics of Neuron and Muscle CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Unité de Biologie Fonctionnelle et Adaptative Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM Hospices Civils de Lyon Physiopathologie et génétique du neurone et du muscle / Pathophysiology and Genetics of Neuron and Muscle Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Service d'Electroneuromyographie et Service de Neurologie C [Hôpital Pierre Wertheimer - HCL] Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Hospices Civils de Lyon Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Hospices Civils de Lyon Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Hospices Civils de Lyon Hospices Civils de Lyon Centre Hospitalier Lyon Sud [CHU - HCL] Centre Hospitalier Lyon Sud [CHU - HCL] Hospices Civils de Lyon Hôpital de la Timone [CHU - APHM] Filière Neuromusculaire Hôpital de la Timone [CHU - APHM] Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Neuro-Oncologie [Hôpital de la Timone - APHM] Neuro-Oncologie [Hôpital de la Timone - APHM] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Lille Neurosciences & Cognition - U 1172 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de référence des Maladies Neuromusculaires AOC Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de référence des Maladies Neuromusculaires AOC Centre de Reference des Maladies Neuromusculaires - Atlantique Occitanie Caraïbe Centre Hospitalier Régional Universitaire de Brest Lymphocytes B, Autoimmunité et Immunothérapies Service de Neurologie [CHU Rennes] CHU Gabriel Montpied [Clermont-Ferrand] CHU Gabriel Montpied [Clermont-Ferrand] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] CHU Charles-Nicolle Département Neurologie [CHU Toulouse] Centre de référence des Maladies Neuromusculaires AOC Centre Hospitalier Universitaire de Bordeaux Centre de reference des maladies neuromusculaires Nantes-Angers, CHU d'Angers et Nantes Hôpital Gui de Chauliac [CHU Montpellier] Service de Neurologie [CHU Nimes] Service de Neurologie [CHU Nice] Service de Neurologie [CHU Nice] IMRB - "Biologie du système neuromusculaire" [Créteil] [GIN] Grenoble Institut des Neurosciences Service de Neurologie [CHU Limoges] CHU Amiens-Picardie CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 CHU Amiens-Picardie Centre Hospitalier Régional Universitaire de Nancy CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Service de Neurologie [CHU Strasbourg] ERN EURO-NMD – European Reference Network for Rare Neuromuscular Diseases Service de Neurologie [CHU Strasbourg] ERN EURO-NMD – European Reference Network for Rare Neuromuscular Diseases Hôpital Raymond Poincaré [AP-HP] Hôpital Raymond Poincaré [AP-HP] Université Paris-Saclay UFR Sciences de la santé Simone Veil CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM
• Publié dans Brain - A Journal of Neurology le 29/10/2020

---

Résumé : Congenital myasthenic syndromes (CMS) are clinically and genetically heterogeneous diseases caused by mutations affecting neuromuscular transmission. Even if the first symptoms mainly occur during childhood, adult neurologists must confront this challenging diagnosis and manage these patients throughout their adulthood. However, long-term follow-up data from large cohorts of CMS patients are lacking, and the long-term prognosis of these patients is largely unknown. We report the clinical features, diagnostic difficulties, and long-term prognosis of a French nationwide cohort of 235 adult patients with genetically confirmed CMS followed in 23 specialized neuromuscular centres. Data were retrospectively analysed. Of the 235 patients, 123 were female (52.3%). The diagnosis was made in adulthood in 139 patients, 110 of whom presented their first symptoms before the age of 18. Mean follow-up time between first symptoms and last visit was 34 years [standard deviation (SD) = 15.1]. Pathogenic variants were found in 19 disease-related genes. CHRNE-low expressor variants were the most common (23.8%), followed by variants in DOK7 (18.7%) and RAPSN (14%). Genotypes were clustered into four groups according to the initial presentation: ocular group (CHRNE-LE, CHRND, FCCMS), distal group (SCCMS), limb-girdle group (RAPSN, COLQ, DOK7, GMPPB, GFPT1), and a variable-phenotype group (MUSK, AGRN). The phenotypical features of CMS did not change throughout life. Only four genotypes had a proportion of patients requiring intensive care unit admission that exceeded 20%: RAPSN (54.8%), MUSK (50%), DOK7 (38.6%) and AGRN (25.0%). In RAPSN and MUSK patients most ICU admissions occurred before age 18 years and in DOK7 and AGRN patients at or after 18 years of age. Different patterns of disease course (stability, improvement and progressive worsening) may succeed one another in the same patient throughout life, particularly in AGRN, DOK7 and COLQ. At the last visit, 55% of SCCMS and 36.3% of DOK7 patients required ventilation; 36.3% of DOK7 patients, 25% of GMPPB patients and 20% of GFPT1 patients were wheelchair-bound; most of the patients who were both wheelchair-bound and ventilated were DOK7 patients. Six patients died in this cohort. The positive impact of therapy was striking, even in severely affected patients. In conclusion, even if motor and/or respiratory deterioration could occur in patients with initially moderate disease, particularly in DOK7, SCCMS and GFPT1 patients, the long-term prognosis for most CMS patients was favourable, with neither ventilation nor wheelchair needed at last visit. CHRNE-LE patients did not worsen during adulthood and RAPSN patients, often severely affected in early childhood, subsequently improved.

---

Fichiers liés : awae124.pdf

---

Source